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The aim of this study was to establish a quality-control method for calcineurin subunit B (CNB) biological activity determi-
nations. CNB enhances the p-nitrophenylphosphate (pNPP) dephosphorylating activity of calcineurin subunit A Δ316 mutant 
(CNAΔ316). A series of CNB concentrations were fitted to a four-parameter equation to calculate the corresponding pNPP 
maximum dephosphorylation rates. Values were calculated based on biological activity references using a parallel line method. 
The method was then validated for accuracy, precision, linearity, linear range, sensitivity, specificity, and robustness. The re-
covery results were greater than 98%. Intra-plate precision was 6.7%, with inter-plate precision of 10.8%. The coefficient of 
determination was greater than 0.98. The linear range was 0.05–50 μg mL1, with sensitivity of 50 μg mL1. Tested cytokines 
did not induce CNAΔ316 dephosphorylation of pNPP. The chosen CNAΔ316 concentration range did not affect activity de-
terminations. 
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CNB is a regulatory subunit of calcineurin (CN) with a 
well-established function of regulating the phosphatase  
catalytic activity of CN (Rusnak and Mertz, 2000; 
Aramburu et al., 2000). CNB also plays additional, 
non-regulatory roles. For example, CNB can significantly 
extend the survival of H22 hepatoma ascites- or S180 sar-
coma tumor-bearing mice and exerts a well-defined thera-
peutic effect on the liver and the lung in nude mouse cancer 
model (Wei et al., 2002). CNB can also stimulate the im-
mune system, as it increases the natural killer activity of 
murine spleen lymphocytes, promotes peritoneal macro-
phage proliferation, enhances phagocytic activity, and  
increases the secretion of cytokines (Wei et al., 2002;  
Jin et al., 2005). Further studies revealed that CNB interacts 
with integrin M and increases TNF-related apopto-
sis-inducing ligand (TRAIL) expression in macrophages, 
thereby inducing tumor cell apoptosis (Liu et al., 2012;  
Su et al., 2012). Furthermore, CNB promotes TNF— 
induced apoptosis, possibly by affecting mitochondrial 
function (Cheng et al., 2012). The remarkable tumor  
suppressive effect and the extremely low incidence of side 
effects of CNB administration render it a promising  
anti-cancer drug. CNB has been developed as a genetically 
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engineered drug, patented in China and the US (Wei et al., 
2003; Wei et al., 2006). A preparatory CNB production 
process has been initiated, and the methods for evaluation of 
CNB molecular weight, isoelectric point, N-terminal amino 
acid sequence, purity, and other objective indicators of 
quality control have been standardized. However, no detec-
tion method for CNB activity has been established. In the 
context of patient treatment, the establishment of a specific 
CNB activity determination method is particularly im-
portant. According to previous studies, CNB regulates the 
activity of CN by interacting with CNA, the catalytic subu-
nit of CN (Rusnak and Mertz, 2000; Aramburu et al., 2000). 
CNB binds to the BBH domain of CNA to regulate its ac-
tivity and stability (Reiter et al., 1999). Binding of calcium 
ions to the four calcium-binding sites of CNB triggers a 
conformation change in CNA, activating CN (Yang et al., 
2000; Feng et al., 1998). Therefore, CNA conformational 
change may be a good choice as CNB activity determina-
tion target. 
Here, we establish a practical CNB activity determina-
tion method. CNA activity is low and this subunit is not 
suitable for industrial detection, storage, and transportation. 
We therefore used CNAΔ316 mutant, one of Loop 7 mu-
tants, which has a higher activity and stability than native 
CNA and retains the characteristics of CNA interaction with 
CNB (Wei et al., 1997; Maynes et al., 2004). The method 
was developed based on the observation that CNB promotes 
the ability of CNAΔ316 to dephosphorylate p-nitrophe- 
nylphosphate (pNPP) (Wei et al., 1997). The method is easy 
to implement, with high stability and quantitative accuracy, 
laying a solid foundation for CNB drug development. 
RESULTS 
An assay for measuring the activity of CNB 
The relationship between the absorption values in each well 
and reaction time was linear, and comprised a typical en-
zyme kinetics curve. Initially, the slope of the plotted curve 
was slightly slow and unstable. When the reaction tempera-
ture equilibrated at the set temperature, the curve reached its 
maximum slope. With a sufficiently long reaction time, the 
curve leveled off due to decreasing substrate concentrations. 
The reaction rate correlated with the amount of enzyme 
when the amount of substrate was not limiting. Thus, Vmax 
was proportional to the amount of the enzyme. The results 
are shown in Figure 1. In the assay, total enzyme activity 
comprised combined enzyme activity of CNAΔ316 subunit 
and the CNAΔ316-CNB complex. 
The relationship between the concentration of CNB and 
Vmax was linear, as determined by the four-parameter re-
gression equation. The lower asymptote reflects the amount 
of CNAΔ316 and the upper asymptote reflects the amount of 
CNAΔ316-CNB. The ratio of the maximum (upper asymp-
tote) to minimum (the lower asymptote) values corresponds 
the proportion of CNAΔ316 activated by CNB (Figure 2).  
 
Figure 1  Enzyme kinetics curve relating reaction time to absorption 
measurements. Note: The kinetics curve represents an example of substrate 
decomposition by CNA316 promoted by CNB, read from one well of 
96-well plate as absorbance versus time. Due to the changing temperature, 
the initial reaction rate is relatively slow. The middle of the curve ap-
proaches a straight line, where the reaction proceeds at the maximum rate 
(Vmax). As the substrate is consumed, the reaction rate decreases. 
 
Figure 2  Dose-response curve between CNB dilution and Vmax. The 
S-shaped curve reflects the maximum decomposition rate of pNPP at dif-
ferent concentrations (dilutions) of CNB, where undiluted CNB prepara-
tion=1. ΔCNA316 and pNPP concentrations, and the temperature were 
constant. Two curves in the figure were used for biological activity value 
referral: ○, represents data for CNB reference material. Δ, represents data 
for CNB sample. 
The data revealed that the activity of CNA could be en-
hanced by up to 18.6 fold in the presence of CNB. The two 
four-parameter regression curves can be used to refer the 
activity values of CNB samples to CNB standard, and for 
quality control of CNB.  
Parallel transformation analysis 
Dose-effect lines of the reference material (standards) and 
CNB samples, plotted as Vmax vs. logarithmic-transformed 
protein dilutions, are shown in Figure 3. The value was 
0.3709. The corresponding P value was 0.7146, greater than 
0.05. Therefore, the difference between the reference mate-
rial and the CNB sample was not significant. The two lines 
were parallel to each other, and the reactions were con-
sistent with each other. 
Accuracy assessments 
The recovery rate reached 98%, close to 100%, indicating a 
minimal effect of the solution formulation of CNB standard  
586 Shi, X., et al.   Sci China Life Sci   June (2016) Vol.59 No.6 
 
Figure 3  Analysis of reaction consistency. The maximum reaction rate 
obtained from the middle segment of the S-shaped curve in Figure 2 shows 
a linear relationship with logarithmic-transformed dilutions of CNB. The 
curves were used to analyze parallelism and to assess consistency of CNB 
samples and CNB reference material. ◇, represent data for CNB reference 
material. Line equation for data fitting, Y=3.138X+12.129 (R2=0.986). □, 
represent data for CNB sample. Line equation for data fitting, 
Y=3.204X+12.017 (R2=0.982). 
and CNB test sample on the test system. This indicated that 
the method is highly accurate. 
Precision assessments 
Results from several independent experiments were ana-
lyzed statistically. The intra-plate precision was less than 
6.7%, and the inter-plate precision was less than 10.8%. 
These results indicated that the precision of the method was 
adequate. 
Linearity testing 
After fitting data from several experiments to the 
four-parameter regression equation, the coefficient of de-
termination (R2) was greater than 0.98. 
Sensitivity assessment 
The lowest CNB concentration beyond the upper inflec-
tion-point of the four-parameter regression curve was ap-
proximately 50 μg mL1. Thus, the sensitivity of this meth-
od was 50 μg mL1. Beyond that point, most CNAΔ316 was 
bound to CNB. The nominal concentration (μg mL1) ratio 
of CNB to CNAΔ316 was approximately 10:1, while the 
molar concentration ratio of CNB to CNAΔ316 was ap-
proximately 32:1. 
Specificity assessment 
Cytokines, such as rhG-CSF, rhIFN-2b, and rhIL-2, did 
not activate the enzymatic activity of CNAΔ316 (data not 
shown). The ability of CNB to activate CNAΔ316 was ef-
fectively inhibited by polyclonal anti-CNB antibodies (data 
not shown).  
Robustness testing 
This method was designed to refer the activity values of 
CNB samples to the CNB standard. Due to the reference 
material applied, the experimental temperature, reaction 
time, and substrate concentrations were robust. However, 
the experiment was affected by the amount of CNAΔ316. 
We tested different CNAΔ316 concentrations in the system. 
This revealed that CNAΔ316 concentrations between 2.5 
and 10 μg mL1 did not affect the shape of the curve. The 
effect of various CNAΔ316 concentrations is shown in  
Figure 4. 
DISCUSSION 
The chromogenic substrate, pNPP, is dephosphorylated 
(decomposed) by CNA to produce a yellow substance with 
an absorption peak at 405 nm (Chaudhuri et al., 2013; 
Kissmehl et al., 1997). CNAΔ316 is a mutated form of 
CNA that retains the activity of the native subunit and its 
ability to be activated by subunit B (Wei et al., 1997; 
Maynes et al., 2004). The mutation increases the stability of 
CNA subunit, making it more suitable for quality control 
experiments.  
This study was designed to establish a quality control 
assay for measuring the activity of the engineered CNB 
product. In other words, to characterize CNB samples using 
CNB reference materials. The formula and calculation of 
biological activity value referrals corresponded to the 
method used for assays with recombinant cytokines, de-
scribed in the general of Chinese Pharmacopoeia. In the 
general, enzyme dilution or dilution factor were used as the 
horizontal ordinate of a four-parameter curve (National 
Pharmacopoeia Committee, 2015). We determined the ac-
tivity of CNB samples using the following formula: 
Ps=Pr×((Ds×Es)/(Dr×Er)). In this formula, Ps and Pr rep- 
resent the biological activities of a CNB sample and CNB 
reference material (U per mL), respectively; Ds and Dr rep- 
 
 
Figure 4  The effect of CNAΔ316 concentrations on Vmax. Each curve 
represents the relationship between CNB dilutions and maximum pNPP 
decomposition rate at the specified CNAΔ316 concentrations. CNAΔ316 
concentrations, bottom to top, were: 2.5 μg mL1, 5 μg mL1, and 10 μg mL1. 
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resent pre-dilution factors of CNB sample and CNB refer-
ence material, respectively; Es represents the dilution factor 
of a CNB sample that generates a response equivalent to 
that generated by 50% effective concentration of CNB ref-
erence material; Er represents the dilution of CNB reference 
material at 50% effective concentration. Accurate protein 
quantification of CNB samples may not be required for the 
referral of biological activity values when this formula is 
employed. The method does not require accurate protein 
quantification or biological activity determination of 
CNAΔ316 (Figure 4), simplifying the calculations and 
minimizing the error associated with computed referrals of 
biological activities. Our method for determination of CNB 
activity established herein is specific and controlled, laying 
a solid foundation for CNB quality control testing.  
Information about the CNAΔ316-CNB complex was ob-
tained from our data, as follows. (i) Results described in the 
“An assay for measuring the activity of CNB” section indi-
cated that the biological activity of CNAΔ316 can be in-
creased up to 18.6-fold by CNB. (ii) Molar ratio of 
CNAΔ316 to CNB in the CNAΔ316-CNB complex was 
approximated using the straight line section of three 
four-parameter curves in Figure 3. Molar equivalents of 
CNB and CNAΔ316 varied geometrically and in equal pro-
portions, suggesting that the same amount of CNAΔ316 and 
CNB was required for the formation of the CNAΔ316-CNB 
complex. The molar ratio of CNAΔ316 to CNB in the 
CNAΔ316-CNB complex was therefore estimated as 1:1. 
(iii) Dissociation constant (Kd) of the CNAΔ316-CNB com-
plex was also estimated. The formula Kd=([A][AB]) 
([B][AB])/[AB] can be applied depending on the nature of 
the compound (Marston et al., 1975; Maekawa, 1975; Kan-
dutsch et al., 1981). Herein, [A] and [B] represent the initial 
molar concentration of CNAΔ316 and the concentration of 
free CNB in the assay, respectively, and [AB] represents the 
molar concentration of the complex formed in the assay. 
([A][AB]) and ([B][AB]) represent molar concentration 
of CNAΔ316 and the equilibrium concentration of CNB, 
respectively. Any point on the four-parameter curve satis-
fies the above equation, and at 50% effective dose (ED50), 
the molar concentrations ([A][AB]) and [AB] are equal. 
The equation can then be simplified to Kd=([B][A])/2. 
Furthermore, Kd can be estimated using the ratio of molar 
concentrations of the CNAΔ316-CNB complex and 
CNAΔ316. A point on the four-parameter curve reflected 
this ratio, and the calculated Kd was in the range of 
2.83×106 to 2.65×107 mol L1. This was close to the pre-
viously calculated CNA Kd range (Rusnak and Mertz, 
2000). 
To conclude, we established a method for the determina-
tion of biological activity of CNB. This method is simple 
and easily standardized, and lays foundations for drug de-
velopment of CNB.  
MATERIALS AND METHODS  
Proteins, materials, and reagents 
Lyophilized CNAΔ316, CNB standard, CNB test sample 
(Beijing Normal University), p-nitrophenylphosphate 
(pNPP) (34047, Thermo Fisher Science, USA), bovine se-
rum albumin (BSA) (ST023 Beyotime, Shanghai), DL-  
dithiothreitol (DTT) (ST040, Beyotime, Shanghai), and 
anti-CNB polyclonal antibody (ab154650, Abcam, USA) 
were used.  
Testing medium comprised 50 mmol L1 Tris-HCl (pH 
7.4), 0.2 mg mL1 BSA, 20 mmol L1 pNPP, 1 mmol L1 
DTT, 1 mmol L1 MnCl2, and 1 mmol L1 CaCl2. Microtiter 
plate reader (Spectrum plus 5, Molecular Device, USA) was 
used in the assays. 
CNB bioassay 
To test the activity of CNB, CNB samples and standards 
were reconstituted in water and diluted to 100 μg mL1 with 
testing medium. Then, 12 two-fold dilutions were serially 
prepared in a 96-well microtiter plate (100 μL per well), in 
duplicate. CNAΔ316 was reconstituted in water and diluted 
to 2.5–10 μg mL1 with testing medium. The solution was 
then added to the same 96-well plate (100 μL per well). The 
above two steps were performed on ice. 
The absorbance was read with a microtiter plate reader 
pre-warmed to 30°C, at 410 nm, in an enzyme kinetics 
mode. A410 values were read every 5 min for 3 h. The re-
sults were recorded. The data were analyzed using a four-   
parameter regression method. 
The maximum decomposing velocity (Vmax) in each well 
was calculated using an enzyme kinetics curve. CNB dilu-
tion and Vmax values were fitted to a four-parameter regres-
sion equation commonly used for curve-fitting analyses in 
bioassays. The following is the four-parameter regression 
model, with the independent value X and dependent value Y: 
Y=(A–D)/(1+(X/C)^B)+D; A, upper asymptote valuation. D, 
lower asymptote valuation. B, slope of the curve. C, half the 
maximum binding dose. Here, we defined CNB dilution as 
X, and Vmax as Y. 
Parallelism analysis 
Reaction consistency between the reference materials and 
the samples was assessed using the distances between the 
inflection points of the four-parameter regression equation 
curve. Data values that were parallel between the reference 
materials and the sample were analyzed using the regression 
coefficient t test.  
Accuracy testing 
CNB reference dilutions, CNB test solutions, and mixed 
dilutions (dilutions of CNB references mixed with CNB test 
solutions at 1:1 ratio) were prepared. The test was per-
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formed in 96-well plates, as specified in the “CNB bioas-
say” section, and the recovery was calculated.  
Precision testing 
Independent assays were carried out on different days. 
Every day, the assays were performed in three different 
96-well microtiter plates. Inter- and intra-plate precisions 
were calculated. 
Linearity, linear range, and sensitivity 
Linearity, linear range, and sensitivity were analyzed using 
the four-parameter regression equation. 
Specificity testing 
The specificity of the method was evaluated by determining 
the effect of therapeutic cytokines, including recombinant 
human granulocyte colony-stimulating factor (rhG-CSF), 
recombinant human Interferon-2b (rhIFN-b), and re-
combinant human Interleukin-2 (rhIL-2), on the OD values 
measured. Serial adjusted dilutions were prepared as de-
scribed in method CNB bioassay. 
Excess of CNB polyclonal antibody was used to neutral-
ize CNB, at 37°C for 30 min, before activity assays. 
Robustness testing 
Different concentrations of CNAΔ316 were pipetted into 
wells of a 96-well microtiter plate to determine the effect of 
different CNAΔ316 concentrations on assay read-outs. 
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